Background. Treatments of eating disorders result too often in partial psychological and physical remission, chronic course, dropout, relapse and death, with no fully known explanations for this failure. In order to clarify this problem, we conducted a three branches study to identify the biochemical background of cognitive-behavioral psychotherapy (CBT), individual psychology brief psychotherapy (IBPP), and psychotherapy-pharmacotherapy with CBT+olanzapine in anorexics (AN) and bulimics (BN) by measuring the levels of plasma homovanillic acid (HVA) for dopamine secretion, plasma 3-methoxy-4-hydroxy-phenylglycol (MHPG) for noradrenalin secretion, and platelet \[3 Hydrogen\]-Paroxetine-binding Bmax and Kd for serotonin transporter function. The data were then compared with psychopathological and physical alterations. Methods. Branch 1 investigated the effects of 4 months of CBT on plasma HVA, MHPG and \[3 Hydrogen\]-Par-binding in 14 AN-restricted, 14 AN-bingeing/purging, and 22 BN inpatients. Branch 2 investigated the effects of 4 months of IBPP on plasma HVA in 15 AN and 17 BN outpatients. Branch 3 investigated the effect of 3 months of CBT+olanzapine (5 mg/day) in 30 AN outpatients. The data are analyzed using one-way ANOVA for repeated measures for the changes between basal and post-treatment biological and psychological parameters, two-way ANOVA for repeated measures for the differences in the psychobiological data in the 3 groups, Spearman's test for the correlations between basal and final changes in the psychological and biological scores.
Study Type
INTERVENTIONAL
Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
112
It is a worldwide known form of psychotherapy for eating disorders
It is a worldwide known form of psychotherapy for eating disorders
It is a worldwide known form of psychotherapy for eating disorders associated with a new antipsychotic with good efficacy on anorexia nervosa
all patients were followed-up monthly with nutritionist and dietitian visits
all patients were followed-up with psychiatric visits with symptomatic drug administration (tranquillizer: delorazepam) where necessary
Villa Garda
Garda, Veneto, Italy
change in brain secretion of Dopamine at 6 months
plasma homovanillic acid (HVA) measured before and after the therapeutic intervention in each branch.
Time frame: 6 months
change in brain secretion of Noradrenaline at 6 months
plasma 3-methoxy-4-hydroxyphenylglycol (MHPG) measured before and after the therapeutic intervention in each branch
Time frame: 6 months
change in brain secretion of serotonin at 6 months
the platelet paroxetine binding (\[3 Hydrogen\]-Par-binding): Bmax (maximum binding capacity) and Kd (dissociation constant) measured before and after the therapeutic intervention in each branch.
Time frame: 6 months
Eating Psychopathology improvement after treatments at 6 months
Eating Disorders Examination-12 (EDE 12)
Time frame: 6 months
Depressive Psychopathology improvement after 6 months
Beck Depression Inventory (BDI)
Time frame: 6 months
Anxiety improvement after 6 months
State-Trait Anxiety Index (STAI) Form-Y-1
Time frame: 6 months
Impulsiveness improvement after 6 months
Barratt Impulsiveness Scale
Time frame: 6 months
Self-rated Biochemical improvement after 6 months
Rosenberg Self-Biochemical Scale
Time frame: 6 months
Personality improvement after 6 months
Temperament and Character Inventory (TCI)
Time frame: 6 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.